HAPA pharm receives GMP certification / Quality assured medical cannabis products

Dortmund (ots) - HAPA pharm ("HAPA" or the "Company") operates production facilities in North Macedonia to grow and process medical cannabis for the sale of pharmaceutical cannabis flos and extracts. On May 1st 2020, the Company has successfully received GMP (Good Manufacturing Practice) approval for both facilities.

This milestone demonstrates HAPA's commitment towards stringent quality assurance on premises and throughout all pharmaceutical processes to manufacture APIs and finished products.

The subsequent EU-GMP certification is due in August 2020 and will allow HAPA to sell its pharmaceutical cannabis products within the European Union.

HAPA pharm is the first German company to cover the full value chain of cannabinoid pharmaceuticals - from growing, packaging and manufacturing of extracts and dried flower to international sales. The company is well positioned to benefit from the rising global demand for pharmaceutical cannabis products.

Controlled quality from the cultivation to the sale

As a globally active producer and wholesaler, HAPA pharm is focusing on the possible uses of medical cannabis, which are becoming ever more important all over the world. Besides the development work, the emphasis here is on producing and selling products of the corresponding standard of quality. HAPA pharm has had two products on the German market since 2019, both now established: the HAPA THC test strip and the AYUCANA CBD oil. The test strip is a quick and easy method for determining the presence of the cannabinoid delta-9-tetrahydrocannabinol (THC) in extracts and cannabis flos. The AYUCANA CBD oil is a full-spectrum extract of EU-certified industrial hemp.

The product range is set to be extended, which is why high-quality extracts of cannabis flowers containing THC have been produced in the certified production facility for the global market since May 2020. In the company's own cannabis cultivation facility in North Macedonia, which meet the standards of Good Agricultural and Collection Practice (GACP), medical cannabis flowers have been grown since November 2019 in order to generate stability data. Production of marketable cannabis flowers will begin in June 2020. With the growing licence for Greece, which has been held since February 2019, plans are on track for cultivation and extraction facility for medical cannabis within the EU. Construction work on the facility is due to be completed in 2021. All production processes are subject to strict guidelines and quality assurance, resulting in safe and effective medicines that meet global and EU requirements.

About HAPA pharm

HAPA pharm is an internationally operating company with a focus on the development, production and distribution of medical cannabis. The company is committed to the controlled cultivation of cannabis plants in Europe and the in-house production of compounded drugs in accordance with GMP guidelines.

Further information can be found at http://www.hapa-pharm.com

Contact:

Publisher HAPA pharm GmbH, Germany Phoenixseestr. 4 / 44263 Dortmund E-Mail: info@hapa-pharm.com

Media contact MCG Medical Consulting Group Mrs. Wiebke Sowen Mörsenbroicher Weg 200 / 40470 Düsseldorf / Germany E-Mail: ws@medical-consulting.de

Additional content: https://www.presseportal.de/pm/144881/4618013 OTS: HAPA pharm GmbH

Original-Content von: HAPA pharm GmbH, übermittelt durch news aktuell